Next Issue
Volume 4, 12
Previous Issue
Volume 4, 06
 
 

GERMS, Volume 4, Issue 3 (09 2014) – 4 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Select all
Export citation of selected articles as:
118 KB  
Opinion
Bacterial Prints in Human Infectious Diseases
by Oana Săndulescu
GERMS 2014, 4(3), 73; https://doi.org/10.11599/germs.2014.1059 - 1 Sep 2014
Abstract
Ample resources have been dedicated to studying bacterial resistance, biofilm formation, and genetic encoding of resistance, metabolism or fitness mutations. [...] Full article
181 KB  
Communication
Daptomycin Resistance in Methicillin-Resistant Staphylococcus aureus: A Report from Southern India
by Anantabotla Vamsimohan, Soham Gupta and Sethumadhavan Muralidharan
GERMS 2014, 4(3), 70-72; https://doi.org/10.11599/germs.2014.1058 - 1 Sep 2014
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) colonization or infection of the wound may cause MRSA bacteremia with increased mortality, making it important to treat the infection. [...] Full article
491 KB  
Article
Efficacy and Safety of Darunavir (Prezista®) with Low-Dose Ritonavir and Other Antiretroviral Medications in Subtype F HIV-1 Infected, Treatment-Experienced Subjects in Romania: A Post-Authorization, Open-Label, One-Cohort, Non-Interventional, Prospective Study
by Otilia Elisabeta Benea, Adrian Streinu-Cercel, Carmen Dorobăț, Sorin Rugină, Lucian Negruțiu, Augustin Cupșa, Dan Duiculescu, Carmen Chiriac, Corina Itu, Liviu Jany Prisăcariu and Ionel Iosif
GERMS 2014, 4(3), 59-69; https://doi.org/10.11599/germs.2014.1057 - 1 Sep 2014
Abstract
Introduction: The aim of the study was to assess the safety and efficacy of darunavir (Prezista®) used in subtype F human immunodeficiency virus – type 1 (HIV-1) infected, antiretroviral therapy (ART)-experienced patients in Romania in routine clinical practice. Methods: This was [...] Read more.
Introduction: The aim of the study was to assess the safety and efficacy of darunavir (Prezista®) used in subtype F human immunodeficiency virus – type 1 (HIV-1) infected, antiretroviral therapy (ART)-experienced patients in Romania in routine clinical practice. Methods: This was a post-authorization, open-label, one-cohort, non-interventional, prospective study conducted at multiple sites in Romania to assess efficacy (CD4 cell count, viral load, and treatment compliance) and safety ([serious] adverse events, clinical laboratory evaluation, and vital signs) of darunavir in combination with low-dose ritonavir (DRV/r) and other antiretroviral (ARV) medications in subtype F HIV-1 infected subjects in naturalistic settings. Seventy-eight subjects were recruited by 9 investigational sites and received 600/100 mg DRV/r twice daily. Results: Treatment with DRV/r administered with other ARV medications resulted in the expected, statistically relevant improvement of CD4 cell count and viral load in subjects eligible for such treatment. In addition, adherence to treatment was high and the treatment-emergent safety profile observed during this study was consistent with the established safety profile of darunavir. Conclusion: DRV/r administered in combination with other ARV medications in subtype F HIV-1 infected subjects in naturalistic settings proved to be an effective and safe treatment in Romania. Trial registration: NCT01253967 Full article
123 KB  
Editorial
Ebola Virus Disease—A Global Threat
by Adrian Streinu-Cercel
GERMS 2014, 4(3), 58; https://doi.org/10.11599/germs.2014.1056 - 1 Sep 2014
Abstract
Ebola and Marburg viruses belong to the same family –Filoviridae– and both have filamentous structures. [...] Full article
Previous Issue
Next Issue
Back to TopTop